BCL11B Is Up-Regulated by EWS/FLI and Contributes to the Transformed Phenotype in Ewing Sarcoma |
| |
| Authors: | Elizabeth T. Wiles Bianca Lui-Sargent Russell Bell Stephen L. Lessnick |
| |
| Affiliation: | 1. Department of Oncological Sciences, University of Utah, Salt Lake City, Utah, United States of America.; 2. Center for Children’s Cancer Research, Huntsman Cancer Institute, Salt Lake City, Utah, United States of America.; 3. Division of Pediatric Hematology/Oncology, University of Utah, Salt Lake City, Utah, United States of America.; Tulane University School of Medicine, United States of America, |
| |
| Abstract: | The EWS/FLI translocation product is the causative oncogene in Ewing sarcoma and acts as an aberrant transcription factor. EWS/FLI dysregulates gene expression during tumorigenesis by abnormally activating or repressing genes. The expression levels of thousands of genes are affected in Ewing sarcoma, however, it is unknown which of these genes contribute to the transformed phenotype. Here we characterize BCL11B as an up-regulated EWS/FLI target that is necessary for the maintenance of transformation in patient derived Ewing sarcoma cells lines. BCL11B, a zinc finger transcription factor, acts as a transcriptional repressor in Ewing’s sarcoma and contributes to the EWS/FLI repressed gene signature. BCL11B repressive activity is mediated by the NuRD co-repressor complex. We further demonstrate that re-expression of SPRY1, a repressed target of BCL11B, limits the transformation capacity of Ewing sarcoma cells. These data define a new pathway downstream of EWS/FLI required for oncogenic maintenance in Ewing sarcoma. |
| |
| Keywords: | |
|
|
